Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID.
Kim Y, Kim S, Kim T, Yun K, Lee S, Lee E Infect Chemother. 2022; 54(3):566-597.
PMID: 36196612 PMC: 9533168. DOI: 10.3947/ic.2022.0141.
Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19.
Seo H, Chong Y Infect Chemother. 2022; 54(2):370-371.
PMID: 35794721 PMC: 9259909. DOI: 10.3947/ic.2022.0045.
References
1.
Lenze E, Mattar C, Zorumski C, Stevens A, Schweiger J, Nicol G
. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(22):2292-2300.
PMC: 7662481.
DOI: 10.1001/jama.2020.22760.
View
2.
Guo C, Harari O, Chernecki C, Thorlund K, Forrest J
. Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials. Am J Trop Med Hyg. 2022; .
PMC: 9128689.
DOI: 10.4269/ajtmh.21-1310.
View
3.
Seo H, Kim H, Bae S, Park S, Chung H, Sung H
. Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial. Infect Chemother. 2022; 54(1):102-113.
PMC: 8987178.
DOI: 10.3947/ic.2021.0142.
View